Zymeworks (ZYME) Stock: Buy, Sell, or Hold?
ZYME - Zymeworks Inc.
$26.24
-0.20 (-0.74%)
▼
5d:
-12.24%
30d:
+5.25%
90d:
+14.26%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When ZYME Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ZYME is down 12.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ZYME is down 12.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$31.16
Based on 1.4% avg growth
INTRINSIC VALUE TODAY
$19.35
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZYME is currently trading at $26.24, which is considered fair relative to its 30-day fair value range of $24.54 to $29.11. From a valuation perspective, the stock is trading at a discount (Forward PE: 22.5) compared to its historical average (56.8). Remarkably, the market is currently pricing in an annual earnings decline of 26.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ZYME is showing sideways momentum. The price is currently testing key support at $26.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ZYME scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $41.75 (+59.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZYME is showing sideways momentum. The price is currently testing key support at $26.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ZYME scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $41.75 (+59.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$24.54 -
$29.11
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
59.6%
Protect Your Profits
Holding ZYME? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 59.1% below Wall St target ($41.75)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$24.54 -
$29.11
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$2.12
(8.1%)
Support & Resistance Levels
Support Level
$26.03
Resistance Level
$31.34
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
22.49
Wall Street Target
$41.75
(+59.1%)
Revenue Growth (YoY)
-90.6%
Valuation Discount vs History
-26.6% cheaper
PE vs Historical
22.5 vs 56.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-26.6%
(market-implied from PE analysis)
1-Year Target
$23.62
(-10%)
2-Year Target
$21.25
(-19%)
3-Year Target
$19.13
(-27%)
3-Yr Target (if PE normalizes)
(PE: 22→57)
$48.30
(+84%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.5, Growth: -1.3%)
$25.20
(+-4%)
Base:
(SPY PE: 20.2, Growth: -1.3%)
$22.59
(-14%)
Bear:
(PE: 17.1, Growth: -1.3%)
$19.20
(-27%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 22.5 to 56.8
Stabilization Target:
$66.26
(+152.5%)
PE Expansion Potential:
+152.5%
Share & Embed Analysis
Last updated: September 12, 2026 11:17 PM ET
Data refreshes hourly during market hours. Next update: 12:17 AM
Data refreshes hourly during market hours. Next update: 12:17 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZYME showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
Advanced ZYME Option Strategies
Professional options setups generated by AI based on today's ZYME price and gamma walls.
